Poolbeg Pharma has completed an Initial Public Offering on AIM
Poolbeg Pharma Plc has raised funds to develop the company.
Poolbeg Pharma is a clinical-stage, infectious disease pharmaceutical company with a capital light clinical model which aims to develop multiple products faster and more cost-effectively than the conventional biotech model, aspiring to become a one-stop shop for Big Pharma seeking mid-stage products to license or acquire. The company was formed from a spin-out of assets from Open Orphan Plc and is headquartered in London, UK.
Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as IPO advisor, assisted Poolbeg Pharma’s management team and shareholders all the way from the start to the successful completion of the IPO. During this process, the team initiated and advised on many aspects, including, among others, securing commitments from investors, asset spin out deal structuring, EIS eligibility, and the IPO pricing and sizing.


Talk to the deal team


Related deals
Ecorobotix has completed a fundraising
Ecorobotix has raised US$52 million. The new capital will enable the company to grow into new markets, expand its product range and build on the existing commercial success of ARA in Europe.
Learn morePresmed Australia has been acquired by ICG
Advanced Health Limited has sold Presmed Australia Pty Ltd (PMA) to ICG.
Learn morePia Mater, a social services firm, has been acquired by SAT Heath
The founders of Pia Mater Ltd. have sold the company to SAT Health.
Learn more